Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03524716 · ClinicalTrials.gov registry record · NA

Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
44
Enrollment target

NCT03524716 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03524716, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

There is a critical need for physical activity interventions in colorectal cancer (CRC). The investigators have developed a digital health physical activity intervention, Smart Pace, which includes a wearable tracker (Fitbit) and text messaging and aims to have patients build up to 150 min/wk of moderate activity. In this study, the investigators propose to expand and improve Smart Pace, including: 1) enrolling patients during chemotherapy; 2) tailoring text messages to individual preferences and treatment timing; and 3) adding resources to support home-based exercise. The study is a 12-week pilot randomized controlled trial (RCT) to evaluate the feasibility of this novel digital health physical activity intervention among 48 CRC patients on chemotherapy. The specific aims are to: 1) Determine the feasibility of the intervention via adherence and attrition, and determine the acceptability of the intervention via questionnaires and semi-structured interviews . 2) Estimate the effect of the intervention vs. usual care on physical activity, QOL, and symptoms at 12-weeks . And 3) Explore the impact of the intervention vs. usual care on fitness, weight, waist circumference, and blood pressure at 12-weeks.

Interventions

  • BEHAVIORAL Fitbit and Text Messages

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2018-03-06
Est. Completion 2020-08-21
Phase NA

What the Registry Record Tells You About NCT03524716

The ClinicalTrials.gov registry entry for NCT03524716 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fitbit and Text Messages is the first listed.

NCT03524716 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03524716 about?

NCT03524716 is a clinical study titled "Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II". There is a critical need for physical activity interventions in colorectal cancer (CRC). The investigators have developed a digital health physical activity intervention, Smart Pace, which includes a wearable tracker (Fitbit) and text messaging and aims to have patients build up to 150 min/wk of mod...

What is the current status of trial NCT03524716?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2018-03-06. Estimated completion is 2020-08-21.

What interventions are being tested in trial NCT03524716?

The interventions under investigation include: Fitbit and Text Messages (BEHAVIORAL).

Who is sponsoring clinical trial NCT03524716?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.